Selective EP4 receptor antagonistic substance for treatment of cancer
This invention provides a medicament for the treatment of cancer, which cause a reduction of cancer. This invention relates to use of a compound which has inhibitory activities against prostaglandin E2 receptor (EP4 receptor) and is represented by the following general formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt for the manufacture of a medicament for the treatment of cancer. The invention relates to a method for treatment of cancer comprising administering the compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt to humans or animals. The compound or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition may be used in combination with one or more second active agents.
1. A method for the treatment of liver cancer, which comprises administering an effective amount of 3-[2-(4-{2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl}phenyl)ethyl]-1-[(4-methylbenzene)sulfonyl]urea or a pharmaceutically acceptable salt thereof to a human or an animal in need thereof.
2. The method according to claim 1 , which further comprises administering a therapeutically effective amount of one or more second active agents known to be useful in the treatment or prevention of liver cancer.
3. The method according to claim 2 , wherein the second active agent is at least one selected from the group consisting of an anti-cancer agent, an antibiotic, an immunosuppressive agent, and a steroid.
4. A method for the treatment of melanoma, which comprises administering an effective amount of 3-[2-(4-{2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl}phenyl)ethyl]-1-[(4-methylbenzene)sulfonyl]urea or a pharmaceutically acceptable salt thereof to a human or an animal in need thereof.
5. The method according to claim 4 , which further comprises administering a therapeutically effective amount of one or more second active agents known to be useful in the treatment or prevention of melanoma.
6. The method according to claim 5 , wherein the second active agent is at least one selected from the group consisting of an anti-cancer agent, an antibiotic, an immunosuppressive agent, and a steroid.
7. A method for the treatment of lymphoma, which comprises administering an effective amount of 3-[2-(4-{2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl}phenyl)ethyl]-1-[(4-methylbenzene)sulfonyl]urea or a pharmaceutically acceptable salt thereof to a human or an animal in need thereof.
8. The method according to claim 7 , which further comprises administering a therapeutically effective amount of one or more second active agents known to be useful in the treatment or prevention of lymphoma.
9. The method according to claim 8 , wherein the second active agent is at least one selected from the group consisting of an anti-cancer agent, an antibiotic, an immunosuppressive agent, and a steroid.
10. A method for the treatment of leukemia, which comprises administering an effective amount of 3-[2-(4-{2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl}phenyl)ethyl]-1-[(4-methylbenzene)sulfonyl]urea or a pharmaceutically acceptable salt thereof to a human or an animal in need thereof.
11. The method according to claim 10 , which further comprises administering a therapeutically effective amount of one or more second active agents known to be useful in the treatment or prevention of leukemia.
12. The method according to claim 11 , wherein the second active agent is at least one selected from the group consisting of an anti-cancer agent, an antibiotic, an immunosuppressive agent, and a steroid.